Are Market Conditions Setting Up A Biopharma M&A Wave?
EY Beyond Borders Report Predicts An Uptake Is Coming
A new EY report contends that declining biotech valuations and the need for large pharma to add pipeline assets may create conditions for a buyer’s market – although year-to-date M&A activity has been lackluster.
